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Reports on the effective treatment of vitiligo have created great interest
among physicians. El Mofty (1, 2) found that the use of crystalline constituents
of the plant Ammi Majus Linn., together with ultraviolet light exposure, re-
sulted in repigmentation of vitiliginous areas in over 75 per cent of patients with
this disorder.
The crude plant has been used orally since ancient times in Egypt. The pa-
tients usually took 4 to 12 grams after meals for 15 days during which time
vitiliginous areas were exposed to sunlight until inflammation and vesiculation
occurred. After the acute reaction subsided, normal pigment was restored in
the previously involved areas of leukoderma. Side effects of this crude prepara-
tion included severe vomiting, diarrhea, coma, abdominal pain, nephritis, hepa-
titis with cirrhosis, and exfoliative dermatitis. Despite the marked toxicity of
this preparation, considerable interest was aroused because of its therapeutic
effect. Concentrated alcoholic extracts of the plant were used orally and locally
with good results. However, the extracts were only slightly less toxic than powder
from the crude plant.
Recently Fahmy and Shady (3—5) reported the isolation of three crystalline
principles from the Ammi majus Linn. fruits which were named Ammoidin,
Majudin, and Ammidin. Schonberg, Sina, Fahmy and Shady (5, 6) found these
compounds to be identical with the previously known chemicals xanthotoxin,
bergapten, and imperatorin, respectively. The three compounds are psoralen
(furo-coumarin) derivatives and are named chemically as shown in Fig. 1 cor-
responding to the above sequence.
El Mofty (1, 2) and others (7—10) used the three compounds separately and
in various combinations. The drugs were given orally and applied locally to the
involved areas. In doses which were effective therapeutically no significant
toxic reactions occurred. Vitiliginous areas became repigmented in as many as
77 per cent of the patients.
The results of clinical and experimental studies with 8-methoxypsoralen
(xanthotoxin, ammoidin) are reported below.
Presented at the Thirteenth Annual Meeting of the Society for Investigative Derma-
tology, Inc., June 8, 1952, Chicago, Illinois.
* From the Department of Dermatology, University of Michigan Medical School, Ann
Arbor.
1 Present address: Department of Dermatology University of Oregon Medical School,
Portland.
t 8-methoxypsoralen was obtained through the courtesy of the Memphis Chemical
Company; Cairo, Egypt and the Paul B. Elder Company; Bryan, Ohio.
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CLINICAL STUDIES
The clinical studies were divided into two parts: first, the effect and toxicity
of 8-methoxypsoralen administered orally to patients with vitiligo; second, the
effect and toxicity of this drug on the erythema response in three light sensitive
individuals with albinism. All patients with vitiligo and albinism were given
the drug orally. On occasions some 8-methoxypsoralen was applied topically.
However, we wanted to determine the effect of a single agent administered in
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FIG. 2. The upper mid-back of case 1 before and after 2 months of therapy
only one way. Throughout the experimental period clinical laboratory studies
consisting of routine urinalyses, complete blood counts, tests for urinary porphy-
rins, prothrombin times* and liver function tests were made. The liver function
tests included thymol turbidity, cephalin cholesterol flocculation, gamma globu-
lin, free and total serum bilirubin, and serum bromsulphalein.
Case 1. C. C., a white female, age 13, with vitiligo. About 6 months before seeking medi-
cal advice, the patient first noted the spontaneous occurrence of depigmented spots over
the upper mid back. These areas enlarged slightly, and other small areas of vitiligo ap-
peared in the same vicinity. Gradually, during the next 6 months, lesions appeared about
* Prothrombin times were carried out to determine whether 8-methoxypsoralen, which
is a coumarin derivative, has an anticoagulant action similar to dicoumarol.
*
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the anterior neck and upper chest. No depigmented area had shown regression. With the
exception of the vitiliginous areas, the physical findings were within normal limits.
The patient took orally 30 mg. of 8-methoxypsoralen daily and used an R.S., G.E. sun-
lamp in erythema doses daily over the involved areas of the hack for a period of 3 months.
After 2 months of this treatment, the lesions on the back filled in from the edges with diffuse
pigmentation. A small amount of perifollicular repigmentation was also noted in the viti-
liginous areas. During the following months complete repigmentation occurred.
After 2 months of oral medication with 8-methoxypsoralen, the anterior neck and upper
chest were exposed to the sunlamp for a period of 1 month. Pigmentation was also restored
in these sites. She noted that exposure of normal skin to strong sunlight for 4 hours on a hot
day did not result in erythema, whereas such exposure prior to therapy had resulted in
marked erythema.
No toxicity followed the use of 8-methoxypsoralen. Laboratory studies showed normal
blood counts, urinalyses, prothrombin times, liver function tests, except for a 1+ cephalin
cholesterol at 48 hours, and no porphyrinuria following 3 months of 8-methoxypsoralen
therapy.
FIG. 3. The arm of case 2 after 4, 6, and 8 months of therapy
Case 2. A. L., a white female, age 27, with vitiligo. Twenty-five years ago, an area of
depigmentation developed spontaneously over the left knee and popliteal space. Ten years
ago, areas of leukoderma appeared about the finger tips of both hands and over the inter-
digital web between the third and fourth digits of the right hand. Shortly thereafter, de-
pigmentation occurred over the other finger webs, dorsal surfaces of the hands, and elbows.
Eighteen months ago, a large patch of depigmentation gradually formed on the extensor
surface of the left forearm; and a small spot of vitiligo appeared on the flexor surface of the
middle of the left forearm. No depigmented areas had shown regression, and the lesions had
been stable for 1 year prior to treatment. With the exception of the vitiliginous areas, the
physical findings were within normal limits.
The patient ingested 10 mg. of 8-methnxypsoralen daily for two months without change
in any of the areas of vitiligo. After 1 month with no medication, the patient was given 50
mg. orally of 8-methoxypsoralen daily and she exposed the involved areas to sunlight fre-
quently for a period of six months. After 4 months of therapy, and shortly after a moderate
sunburn of the vitiliginous areas, perifollicular repigmentatinn was noted over the left
elbow, the left thumb, and particularly over the extensor surface of the left forearm. The
patient discontinued therapy for a period of 3 months during which time there was no change
in the newly repigmented areas. She then took 30 to 50mg. orally of 8-methoxypsoralen daily
and used an ES., G.E. Sunlamp daily in erythcma doses over the involved areas for 4
months. During this time perifollicular repigmentation increased in all vitiliginous areas
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except over the knuckles. At this point three sites of vitiligo were treated locally with
Thorium X in a concentration of 150 mierocuries or 1000 e.s.u. per cc. of base. One site was
treated with an alcoholic solution, another with an ointment, and the third with 0.1 per cent
8-methoxypsoralen added to the alcoholic solution. The size of the lesions was determined,
and 1 cc. of the various prepnrations was used to cover 100 cm.2 of involved area. On ex-
amination two weeks later, marked erythema and vesieulation were noted in the vitiliginous
areas. Hyper-pigmentatidn was pronounced in the normal skin areas which came in contact
with Thorium X. Thorium X did not increase repigmentation in any of the test areas al-
though it did cause darkening of the perifollieulnr repigmentation which had returned
previously. No toxicity to 8-methoxypsoralen occurred.
Laboratory data showed normal blood counts, urinalyses, prothrombin times, liver
function tests, and no porphyrinuria during and following 20 months of intermittent therapy
with 8-methoxypsoralen.
Fin. 4. Lesions on the face of case 3 before and after 5 months of therapy
Gese S. M. F., a Negro female, age 15 months, withvitiligo. Six months prior to examina-
tion the patient's parents noted over a period of 1 month the spontaneous occurrence of
depigmentation about the medial portion of the right orbit, right upper lip, and right tem-
poral region. The parents were greatly concerned about the patient's appearance. The de-
pigmented areas had shown no regression, but had remained stable in size, and no new sites
had developed during the five months preceding examination. With the exception of the
vitiliginous areas, the physical findings were within normal limits.
The patient ingested 10 mg. of 8-methoxypsoralen each day and exposed the involved
areas to erythema doses of sunlight whenever possible for a 12 month period beginning in
May 1951. Three months after initiating treatment, normal pigmentation began to fill in
the areas of vitiligo from the edges. In five months there was considerable return of pigmen-
tation along the right upper lip and right lower eyelid. Pigmentation also increased along
the medial portion of the right upper eyelid and in the spot over the right temporal region.
By the eleventh month, the area about the mouth had entirely filled in with normal pigment.
One month later the area along the medial margin of the orbit began to expand by gradually
becoming depigmented at all margins.
No toxicity to the use of 8-methoxypsoralen was noted. The child gained 10 pounds over
the period of treatment, and growth and development were normal.
Laboratory data showed normal blood counts, urinalyses, and no porphyrinuria during
and following the twelve months of 8-methoxypsoralen therapy.
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Case 4. F. S., a white male, age 33, with vitiligo. Seventeen years agn, the patient first
nnted the spnatanenus neeurrenee of depigmentatinn over the upper hack and shnulders.
During the succeeding years, other leukodermic areas appeared over the anterior and pos-
terior trunk, neck, face, and upper extremities. No depigmented areas had shown regression.
The lesions had remained stahle for the last few years, and no new sites had developed. The
family history was of interest in that the patient's father and brother also had vitiligo.
Except for the vitiliginous areas, the physical findings were within normal limits.
The patient took 10 mg. orally of S-methoxypsoralen each day and exposed the involved
areas to erythema doses of sunlight whenever possible for a period of 4 months beginning in
February, 1951. The patient was next seen in September, 1951, at which time he stated that
he had not become sunburned in the involved areas during the summer despite a more than
usual amount of exposure to sunlight. On examination, no repigmentation was noted in any
of the vitiliginous areas. The patient then took 10 to 30 mg. orally of 8-methoxypsoralcn
each day and used an R.S., G.E. Sunlamp daily on the involved areas in erythema doses
over a 9 month period. He also exposed these areas to sunlight whenever possible. At the
end of this time the patient stated that there was less reaction in the involved areas on ex-
posure to sunlight and that a small area of vitiligo beneath his chin had become repig-
mented. Upon examination under the Wood's lamp, pigmentation in the vitiliginous patches
could be seen. The patient was a farmer who for the 15 years preceding treatment could not
work outside on a sunny day unless all vitiliginous areas were covered. Since receiving treat-
ment, he has been able to work in the fields without taking such precautions.
At times the patient noted vague feelings of nausea and increased nervous tension while
taking 20 mg. of the drug daily. These side effects did not necessitate discontinuing the
medication.
Laboratory data showed normal blood counts, urinalyscs, liver function tests, pro-
thrombin times, and no prophyrinuria during and following 1 year's treatment with 5-
methoxypsoralen.
Case 5. G. S., a white male, age 49, with vitiligo. This patient, a brother of F. S., first noted
the spontaneous occurrence of depigmentation of the chin 18 months prior to examination.
Other small areas of leukoderma appeared over the face, neck, upper extremities, and
scrotum during the following 9 months. No depigmented areas had shown regression. The
lesions had remained stable for 9 months, and no new sites had developed during the period
of observation. With the exception of the vitiliginous areas, the physical findings were
within normal limits.
The patient ingested 10 to 30 mg. of 8-methoxypsoralen daily and used an R.S., G.E.
Sunlamp in erythema doses daily over the involved areas for a period of 9 months. He also
exposed these areas to sunlight whenever possible. In 6 months slight diffuse brown pigmen-
tation appeared in a few of the vitiliginous areas over the patient's face. Gray hair in these
areas grew out black. In S months the patient reported that he was able to tolerate sunlight
on the depigmented areas much better than before treatment. At times ho complained of
vague feelings of nausea, opigastric distress, and increased nervous tension while taking
20 to 30 mg. of the drug daily. These side effects did not necessitate discontinuing the
medication.
Laboratory tests showed normal blood counts, urinalysos, liver function tests, except
for a 1+ ccphalin cholesterol at 48 hours, prothrombin times, and no porphyrinuria during
and following treatment with S-methoxypsoralcn for 1 year.
Case 6. H. L., a white female, age 36, with vitiligo. Three years ago, the patient first
noted the spontaneous occurrence of dcpigmentation over the dorsal surfaces of the hands.
During the last three years the patient developed areas of vitiligo over the forearms. No
depigmcnted areas had shown regression. The patient complained of the unsightly ap-
pearance of the lesions and of sunburning in the involved regions. With the exception of the
vitiliginous areas, physical findings were within normal limits.
The patient took 20 mg. orally of S-mcthoxypsoralon each day, and for a period of 6
weeks u-as given daily increasing doses of ultraviolet light with a Hanovia ultraviolet lamp
304 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
on the involved areas of the hands and forearms. She reached a final leveL of S minimal
erythema doses. No definite return of pigmentation was noted following treatment. Five
months afterwards, the patient's ultraviolet light sensitivity time, tested in the previously
treated vitiliginous areas, was 2 minutes, or 4 minimal erythema doses, suggesting a de-
crease in ultraviolet light sensitivity despite the lack of apparent repigmentation. She again
ingested 20 mg. of 8-methoxypsoralen each day and exposed the involved areas to sunlight
whenever possible for a period of 2 months. No return of pigment was noted. However, the
areas had not sunburned as they did prior to therapy. The patient noted diarrhea if she took
more than 20 mg. of S-methoxypsoralen daily.
Laboratory data showed normal blood counts, urinalyses, liver function tests, pro-
thrombin times, and no porphyrinuria following the last 2 months of S-methoxypsoralen
therapy.
Case 7. F. W., a white female, age 31, with vitiligo and congenital abnormalities of the
fingers and toes. Nineteen years ago, the patient first noted the spontaneous occurrence of
depigmentation about the mouth. Since then she had developed extensive areas of vitiligo
over the body surface, particularly in the covered areas. Hecently new areas of vitiligo were
noted on the flexor surfaces of the forearm. It was possible that part of the vitiliginous area
had become repigmented spontaneously since the onset of the disease. The family history
was of interest in that the patient's grandfather, her father's cousin, a nephew, and a sister
all had vitiligo.
On physical examination shortening and radial deviation of the fifth digit of each hand
were noted. In addition there was ulnar deviation of the third finger of each hand. Webbing
was present between the second and third toes of each foot. With the exception of the
vitiliginous areas, the remaining physical findings were within normal limits.
The patient took 30 mg. orally of S-methoxypsoralen each day and used an R.S., G.E.
Sunlamp daily in erythema doses to the involved areas for a period of 1 month. In addition
three sites of vitiligo were treated locally with Thorium X in a concentration of 150 micro-
curies per cc. of base. One site was treated with an alcoholic solution, another with an oint-
ment, and the third with 0.1 per cent 8-methoxypsoralen added to the alcoholic solution.
The size of the lesions was determined, and 1 cc. of the various preparations was used to
cover 100 cm.2 of involved surface.
All areas treated with Thorium X became very erythematous and slightly edematous
within 48 hours. In 4 days hyperpigmentation occurred in the area of normal skin in contact
with Thorium X. Twenty days after the applications the vitiliginous areas were still ery-
thematous and mild desquamation was present in all treated sites. Hyperpigmentation of
normal skin areas was very marked and showed no evidence of fading. No areas of vitiligo
showed any repigmentation. The patient developed an eruption of typical pityriasis rosea
about 1 week following the use of Thorium X. Although there were lesions over the entire
trunk, including the vitiliginous areas, none developed in the sites treated with Thorium
X. No toxicity to the use of 8-methoxypsoralen occurred.
Laboratory data showed normal blood counts, urinalyses, prothrombin times, liver
function tests, except for a 3+ cephalin-cholesterol flocculation test at 48 hours, and no
porphyrinuria after 4 weeks of treatment with 8-methoxypsoralen.
Case 8. D. E., a Negro female, age 15, with vitiligo. Eight years ago the patient first
rioted the spontaneous occurrence of depigmentation over the left upper chest followed by
areas of depigmentation over the left arm and forearm and left fourth and fifth digits. Four
years ago areas of leukoderma appeared over the left upper back. The patient felt that a
few of the vitiliginous areas had filled in slightly with normal pigmentation during the last
2 years. With the exception of the vitiliginous areas, the physical findings were within
normal limits.
The patient took 30 mg. orally of S-methoxypsoralen daily and used an ES., G.E. Sun-
lamp in erythema doses daily on the involved areas for a period of 7 months. In the last
months three sites of vitiligo were treated locally with Thorium X in a concentration of
150 microcuries per cc. of base. One site was treated with an alcoholic solution, another with
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an ointmenl, and the third with 0.1 per cent 8-metlioxypsoralen added to the alcoholic solu-
tion. The size of the lesions was determined, and 1 cc. of the various preparations was used
to cover 100 cm.2 of involved surface.
All the Thorium N treated areas became very erythematous and slightly edematous
within 48 hours. In about 8 days hyperpigmentation \vas noted in the normal ski u areas in
contact with Thorium X. Twenty days after the applications the depigmented areas were
still erythematous, hyperpigmentation of the normal skin areas remained, and moderate
desquamation was evident. No areas of vitiligo had shown any repigmentation. No toxicity
was noted to the use of 8-methoxypsoralen.
Laboratory data showed normal hlood counts, urinalyses, liver function tests, pro-
thromhin times, and no porphyrinuria during and following treatment for 7 months with
8-methoxypsoralen.
Gem 9. D. D., a white female, age 23, with vitiligo. Twelve years ago the patient first
noted the spontaneous occurrence of depigmentatiou over the knees and volar aspects of
the wrists. During the last four years, the patient developed successive areas of vitiligo of
the ankles, finger tips, axillne, trunk, genitalia, and anal arid perioral regions. No depig-
mented areas had shown regression. The lesions had remained stable for the last year, arid
no new sites of vitiligo had developed during the period of observation. With the exception
of the vitiliginous areas, the physical findings were within normal limits.
The patient took 30mg. orally of 8-methoxypsoralen each day and used an ES., G.E.
Sunlamp in erythema doses daily on the involved areas for a period of 2 months. In the last
month three sites of vitiligo were treated locally with Thorium N in a concentration of
150 microcuries per cc. of base. One site was treated with an alcoholic solution, another
with an ointment, and a third with 0.1 per cent 8-methoxypsoralen added to the alcoholic
solution. The size of the lesions was determined, and 1 cc. of the various preparations was
used to cover 100 cm.2 of involved surface.
All the Thorium X treated areas became very erythematous nod slightly edematous
within 48 hours. In 4 days hyperpigmentatiou was noted in the normal skin areas in contact
with Thorium N. The vitiliginous areas were still erythematous. Twenty days after the
applications, the depigmented areas were no longer erythematous; however, the hyper-
pigmentation of the normal skin areas had not decreased. No areas of vitiligo had shown
any repigmentation. No toxicity resulted from the use of 8-methoxypsoralen.
Laboratory data showed normal blood counts, urinalyses, prothromlon times, and liver
function studies except for a 2+ cephalin cholesterol at 48 hours, and no porphyrinuria
after 2 months of therapy with S-methoxypsoralen.
Of the nine patients with vitiligo treated with 8-methoxypsoralen, seven were
females and t\vo males. Three patients showed striking improvement, two
showed less but definite improvement, and four showed no change.
The patients ranged in age from 15 months to 49 years and were treated for a
period of 1 to 20 months. The daily dose of the drug varied from 10 to 50 mg.
orally given in divided doses snpplied in 10 mg. capsnles. Six of the patients
showed no reaction to the drug, and three had mild symptoms not requiring
discontinuation of the medication. One patient had nausea and increased nervous
tension, the second, nausea and epigastric distress, and the third, diarrhea if
the daily dose was greater than 20 mg. All laboratory studies, except for t\vo, 1 +
one 2+, and one 3+ cephalin-cholesterol flocculation tests after 48 hours, were
negative. Since all 24 hour tests were negative, no significance was attached to
the one, two, and three plus results.
During the above studies it was observed that three of the nine patients de-
veloped marked increase in tolerance to ultraviolet light. It was not known
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whether this inhibition of the erythema reaction to sunlight was due to previous
exposure to ultraviolet light (ii) or to the drug. To study this problem further,
8-methoxypsoralen was given to three individuals with albinism; and the mini-
mal erythema dose responses were followed. All tests for light sensitivity were
performed at new sites each time.
Case 10. K. W., a white male, age 24, with albinism. The patient had very fair skin, white
hair, blue-grey eyes, lateral nystagmus, and photophnbia. Except for a few black beard hairs
and one minute pigmented macule on the mid-back, no evidence of normal melanin pigmen-
tation was present. The patient did not become tanned on exposure to sun.
The patient ingested 30 mg. of 8-methoxypsoralen daily for 3 months. His ultraviolet
light erythema time prior to and 3 weeks after beginning treatment was 15 seconds. At the
end of 2 months of treatment, the patient's ultraviolet light erythema time was 30 seconds,
indicating a definite decrease in sensitivity. The patient noticed no decrease in photophobia,
hut he believed that his skin was less photosensitive on exposure to sunlight following treat-
ment. No toxicity resulted from the use of 8-methoxypsoralen.
Laboratory data showed normal blood counts, urinalyses, prothrombin times, liver
function studies except for a 1+ cephalin cholesterol at 24 and 48 hours, and no porphy-
rinuria following 3 mnnths of treatment with 8-methoxypsnralen orally.
Case 11. J. H., a white male, age 32, with albinism. The patient had very fair skin, white
hair, pink eyes, lateral nystagmus, and photophobia. There was no evidence of normal
melanin pigmentation.
The patient took 30 mg. orally ef 8-methoxypsoralen daily for 3 months. His ultraviolet
light erythema time prior to therapy as well as 4 weeks afterwards was 5 seconds. At the
end of 2 months of treatment, the ultraviolet light erythema time was 30 seconds, indicating
a definite decrease in sensitivity. After 3 months therapy, the erythema time was 15 seconds.
The patient noticed no decrease in photophobia, but he believed that his skin had become
less photosensitive on exposure to sunlight. No toxicity resulted from the use of 8-methoxy-
psoralen.
The laboratory data showed normal blood counts, urinalyses, liver function studies,
except for a 1+ cephalin cholesterol at 48 hours, prothrombin times and no porphyrinuria
during and following 3 months of treatment with 8-methoxypseralen orally.
Case 12. D. W., a white female, age 19, with albinism. The patient had very fair skin,
white hair, blue eyes, lateral nystagmus, and photophobia. No evidence of normal melanin
pigmentation was present.
The patient took 30 mg. orally of 8-methoxypsoralen daily for 2 months. Prier to therapy
her ultraviolet light erythema time was 10 seconds. After treatment for 1 month it was 15
seconds, and after 2 months it was 10 seconds, suggesting a possible decrease in sensitivity.
She was able to swim outdoors en a hot sunny day for 1 and hours without showing any
crythema when examined 15 hours after exposure. The patient stated that such exposure
prior to therapy would have produced a marked reaction. No toxicity resulted from the use
of 8-methexypsoralen.
Laboratory data showed normal blood counts, urinalyses, prothrombin times, liver func-
tion tests, except for a 2+ cephalin cholesterol at 24 hours and a 3+ reaction at 48 hours,
and no prophyrinuria during and following 2 months of treatment with S-mcthoxypseralen
orally.
Two of the albinos were treated for 3 months and the third for 2 months. All
showed decreased sensitivity to ultraviolet light. Two stated that they no longer
wore hats when out in the sun. There was no effect on the photophobia or lateral
nystagmus.
None of the albinos developed any symptoms from the drug. All laboratory
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studies other than the cephalin cholesterol flocculation test were negative. One
patient showed a 1 + test at 24 and 48 hours after 3 months of therapy, a second
showed a 1+ test in 48 hours after 3 months and a third showed a 2+ at 24
hours and a 3+ at 48 hours after 2 months.
TOXICITY STUDIE5
Recent reports showed that for guinea pigs the minimal lethal (lose was 400 mg. per kg.
for 8-methoxypsoralen and 800 mg. per kg. for 8-isoamyleneoxypsoralen (12). Death from
8-methoxypsoralen was attrihuted to adrenal hemorrhage and from 8-isoamyloneoxy-
psoralen to acute necrosis of the liver. Guinea pigs given sublethal doses of 200, 250, 300 and
350 mg. per kg. orally and sacrificed after 30 hours showed cloudy swelling, fatty degenera-
tion, and acute hemorrhagic necrosis of the liver. The kidneys were severely congested.
1-lcmaturia was present. At doses of 300 mg. per kg. there was congestion and lipoid depletion
of the adrenals. Similar doses of 8-isoamyleneoxypsoralen produced only some cloudy
swelling of the liver. Repeated oral administration of 8-methoxypsoralen in doses of 1 and
2 mg. per kg. for 5 months had no effect on growth hut resulted in liver necrosis in some
of the animals.
For mice the minimal lethal dose was 310 mg. per kg. for 8-methoxypsoralen, and 330 mg.
per kg. for 8-isoamyleneoxypsoralen (2). In our experiments, adult male mice were divided
into 5 groups of 8 animals and given 8-methoxypsoralen by intraperitoneal injection in
5% acacia (34 ml. volume) in doses of 100, 200, 300, 400, and 600 mg per kg. At the end of
48 hours, deaths occurred as follows: 1 in the 200 mg. per kg. group, 2 in the 300 mg. per kg.
group, 3 in the 400 mg. per kg. group, and 4 in the €00 mg. per kg. group.
In the course of studies to determine whether these drugs could alter the effect of large
amounts of x-ray on adult female rats, it was observed that when 8 control rats were given
200 mg. per kg. of 8-methoxypsoralen by intraperitoneal injection in 5% acacia, 3 died in
24 hours and the rest lived (13). Of eight rats treated similarly hut given 560 r, 2 died in 24
hours and the rest lived. Of eight rats treated as above hut given 900 r, 2 died in 24 hours
and the rest in the following two weeks. The early deaths probably resulted from toxicity
to 8-methoxypsoralen and the late deaths from radiation. These studies showed that of 24
rats given 200 mg. per kg. 7 died within 24 hours and the rest lived. Of 8 rats given 400 mg
per kg. and 900 r, 7 died in 24 hours.
El Mofty gave three patients 150 mg. of 8-methoxypsoralen in divided doses
3 times daily (2). Severe nausea, vomiting, giddiness, sense of fatigue, and
headache were experienced by all. One patient developed diarrhea. TJrinalyses
were negative. Three patients given 100 mg. in divided doses showed less severe
symptoms than those seen in patients receiving 150 mg. per kg. It was claimed
that a dose of 50 mg. produced no symptoms. Doses of 8-isoamylenexypsoralen
of 1 mg. per kg. produced no symptoms. The drugs had no effect on three pa-
tients w'ith bronchial asthma and two patients with hyperthyroidism. A patient
with a papular necrotic tubereulid could tolerate only half of the expected dose.
A patient with mild diabetes mellitus who did not require insulin became worse.
Our studies showed that a child of 15 months could take 10 mg. daily for
months without deleterious effect on growth or weight. For adults, doses rang-
ing from 20 to 50 mg. were given for long periods of time. There was great varia-
tion in individual tolerance. Whereas one person took 50 mg. daily without diffi-
culty, another did well on 20 mg. daily but developed symptoms when given
30 mg. The symptoms observed were nausea, epigastrie distress, increased
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nervous tension, and diarrhea. One of our patients developed pityriasis rosea
while on the drug. It was our feeling that this eruption was not related to the
drug. Extensive laboratory studies were negative except for the cephalin choles-
terol flocculation test which was carried out on 11 of the 12 cases. Of the 11 pa-
tients, 7 had questionable changes in the cephalin cholesterol flocculation test
after receiving the drug for 1 to 3 months. In 5 cases only the 48 hour tests were
positive; in the other two, one was 1+ and the other 2+ at 24 hours.
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FIG. 5. Molecular extinction coefficient of 8-methoxypsoralen
The above data indicate that up to 50 mg. of 8-methoxypsoralen daily in
divided doses is safe for adults. It appears worthwhile to do cephalin cholesterol
flocculation tests monthly for 3 months and then at less frequent intervals to
check liver function.
IN VITRO STUDIES
All in vitro experiments were carried out with 8-methoxypsoralen before and
after irradiation of the compound with ultraviolet light. This procedure was
followed because in the treatment of vitiligo, the drug is inactive alone, ultra-
violet light being required for a therapeutic effect. It is possible that 8-methoxy-
psoralen is converted to a new compound which in turn may be the active agent
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Xi 8-ISQAMYLENEOXYPSORALEN
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stimulating the melanocyte* to produce pigment. Another possibility is that the
drug and ultraviolet light potentiate one another's effect on the pigment produc-
ing cell.
Both 8-methoxypsoralen and 8-isoamyleneoxypsoralen absorb greatly through-
out the ultraviolet light spectra. The molecular extinction coefficient curves
are shown in Fig. 5. If a dilute solution of 8-methoxypsoralen is irradiated with
ultraviolet light for 3 and 6 hour periods of time, a decrease in optical density
is obtained as shown in Fig. 6. Thus it appears that irradiation of 8-methoxy-
psoralen with ultraviolet light destroys the compound. Ascorbic acid and ferrous
ions have no apparent effect on this change in absorption. When a relatively
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FIG. 6. The effect of ultraviolet light oa the optical deosity of 8-methoxypsoralcn 12
mg. per liter ia 10 per cent ethanol. Ultraviolet irradiatioo was obtaioed from ao R.S.,
G.E. Sunlamp 2 inches ahovc the solution. The volume of each solution was kept constant!
by addition of 10 per cent ethanol as rapidly as the solution evaporated.
concentrated solution is irradiated, no change is observed in the ultraviolet
absorption spectrum; hut a yellow colored solution is produced. The absorption
of this yellow solution is shown in Fig. 7. The solution prior to irradiation does
not give any absorption in this region. Exposure of these solutions to light from
an ordinary incandescent bulb did not bring about the above changes.
One half ml. portions of the dilute and 0.4 ml. of the concentrated solutions
before and after irradiation were added to 0.2 ml. mammalian tyrosinase (ap-
proximately 3 units) (14'), 0.5 ml. substrate (0.5 mg. tyrosine or dopa in buffer)
* In accordance with terminology adopted at the Pigment Cell Conference (N. Y., 1951),
the term melanocyte will he used to designate the mature pigment forming cell, thus re-
placing the older term melanoblast.
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and sufficient 0.1 M phosphate buffer at pH 6.8 to make a total volume of 3 ml.
Oxygen uptake measurements at 38°C on the tyrosine-, dopa-, and glutathione
inhibited-tyrosinase reactions were negative. No effect on pigment formation
was observed. The preparations did not affect the tyrosine or dopa histochemical
tests in human skin slices.
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Fj. 7. The effect of ultraviolet light on the optical density of 8-methoxypsoralen 666.5
mg. per liter in a solution of 1 part ethanol, 0.4 parts 10 per cent Tween 20 and 4.6 parts
water. Ultravio1et irradiation was obtained from an R.S., G.E. Sunlamp 2 inches above the
solution. The volume of the solution was kept constant by adding fresh solvent as rapidly
as the solution evaporated.
PSORALEN
Fic.. 8. Psoralen
These solutions were also tested to determine whether they could act as the
melanocyte stimulating hormone (melanophore hormone). Tests with isolated
frog skin were negative.
TERMINOLOGY
In 1933, Jois, Manjunath and Venkatia Rao (151 isolated a substance from
the seeds of Psoralea corylifolia Linn. to which they assigned the name psoralen.
STUDIES WITH 8-METHOXYPSORALEN IN VITILIGO 311
This chemical consisting of a coumarin and furo group is the nucleus for the
compounds discussed in this paper. The nucleus and the method of numbering
these compounds is shown in Fig. 8. In 1911, Priess (16) and Thorns (17) iso-
lated 8-methoxypsoralen from Faqara xanthoxyloides and gave it the name
xanthotoxin. In 1947, Fahmy and Shady (3) used the term ammoidin. Originally,
8-isoamyleneoxypsoralen, isolated from Imperatoria ostrnthium was called
imperatorin (18) and later ammidin (3). Since 1891, 5-methoxypsoralen, isolated
from oil of bergomot, had been known as bergapten (19) and later as majudin
(4). We believe it is best to retain the correct chemical names as shown in Fig. 1.
For general use, the term psoralen derivative is suggested.
SOURCE OF PSORALEN COMPOUNDS
The psoralen derivatives discussed in this paper have been isolated from a
variety of natural sources including, expressed citrus peel oils, bergomot oil,
and the plants, Ammi majus Linn., Angelica archanglica, Angelica glabra, Seseli
indicum, Sicimmia laureola Hook, Imperatoria ostruthium, Aegle marmelos, Ruta
chalapensis, Ruta graveolens, Luvanga scandens and others. In addition, these
compounds have been made synthetically. The psoralens present in natural
oil, such as bergomot, stimulate the melanocytes and produce the hyperpig-
mentation seen in Berloque dermatitis.
DISCUSSION
Many substances have been used to treat vitiligo, including itamins of the
B complex (especially PABA), pituitary extracts, heavy metals and psoralen
derivatives. With the exception of the recently purified psoralen compounds
therapy has always had a variable effectiveness. Our clinical and animal toxicity
studies parallel those of El Mofty (2) and Elwi (11).
The Egyptian workers used mixtures of 8-methoxy- and 8-isoamyleneoxy-
psoralen both locally and orally, followed by exposure of the vitiliginous areas
to ultraviolet light, and reported results better than ours. We used 8-methoxy-
psoralen orally only and exposed the involved areas to ultraviolet light. It is
planned to try mixtures of the psoralen derivatives in future studies. TThfor-
tunately, no simple system is available by which compounds can be tested. Clini-
cal evaluation is obviously difficult Lecause many patients must be studied for
long periods of time before definite conclusions can be reached.
When properly used the psoralen derivatives are not toxic. The LD50 for rats
and mice is about 400 to 600 mg. per kg., while the therapeutic dose for human
beings is less than 1 mg. per kg. When symptoms of nausea and gastrointestinal
distress occur, the dosage should be decreased. The only clinical laboratory
study considered important is the cephalin cholesterol flocculation test. This
determination should be carried out once a month for 3 months and then at
less frequent intervals.
Individuals handling the drug should not let it come in contact with the
skin. One of our laboratory workers' arm came in contact with an alcoholic solu-
tion of 8-methoxypsoralen. Shortly thereafter, following exposure to ultraviolet
light, he developed a hyperpigmented spot on the arm. Fig. 9.
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Until now there have been no reports on the use of radiant energy, other than
ultraviolet light, given in conjunction with oral and local therapy. Thorium X
was used locally on 3 of our patients because this substance is kno\vn to be
excellent for stimulating pigmentation. No improvement was noted following
a single application of Thorium X. However, this procedure merits further test-
ing.
It is of interest to speculate on the mechanism of action of these drugs. It is
not known whether ultraviolet brings about conversion of the psoralen deriva-
tives to more active substances or whether the two factors act synergistically to
produce an increase in melanin formation. A combination of both mechanisms
might be at work.
Fio. 9. Hyperpigmentation on the arm following exposure to ultraviolet light in a
laboratory worker who accidentally came in contact with an alcoholic solution of
8-mcthoxypsoralen.
The psoralen compounds before and after exposure to ultraviolet light have
no effect on tyrosine- or dopa-tyrosinase reactions or on the glutathione in-
hibited reaction. Also, the substances do not act as does the melanocyte stimu-
lating hormone. Coumarins are known to inhibit sulfhydryl groups. While such
inhibition was riot shown from our studies with psoralens and glutathione in-
hibited tyrosinase, the possibility of inactivation of SH groups by psoralens
should be tested. An agent, at the proper location in the skin, that could react
with SR groups, plus ultraviolet light—which is known to inactivate SH groups
—might stimulate melanin formation. In addition, the chemical structures of
the psoralen derivatives partly resemble that of alloxan. Alloxan, which is
known to react with sulfhydryl groups, may produce diabetes mellitus in animals
through such a reaction, (20). A patient with diabetes mellitus, who did not
require insulin before receiving psoralcn derivatives, lost weight; and insulin
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was necessary for diabetic control afterwards (2). These findings are consistent
with inhibition of sulfhydryl groups by the psoralens.
The apparent increase in tolerance to ultraviolet light after ingestion of the
drug is in marked contrast to the increased sensitivity to ultraviolet light follow-
ing local application. Since these substances absorb strongly throughout the
ultraviolet region and have absorption peaks at 3000 and 2500 A, it is possible
that they absorb erythema producing rays in much the same way as natural
melanin, which protects the skin by absorbing visible and ultraviolet light.
These drugs should be tried on patients with various light sensitivity diseases
such as lupus erythematosus, xeroderma pigmentosum, hydroa aestivale, etc.
They should also be used with ultraviolet light in those disorders in which ultra-
violet light acts therapeutically, such as psoriasis.
Although it is not known why local use of the drug results in increased sensitiv-
ity to ultraviolet light, it may be of significance that the locally applied prepara-
tions supply a very high concentration of the drug to the skin, whereas oral
therapy allows only a very low concentration to reach the skin.
SUMMARY
1. Oral administration of 8-methoxypsoralen (xanthotoxin, ammoidin), to-
gether with exposure of areas of vitiligo to ultraviolet light, is effective treatment
for some cases of vitiligo.
2. Oral use of this drug decreases the erythema response of patients to ultra-
violet light, whereas local application increases this response.
3. In appropriate doses 8-methoxypsoralen is well tolerated by patients.
Complete blood studies, urinalyses, examinations for urinary porphyrins, pro-
thrombin times, and liver function tests, except the cephalin cholesterol floccula-
tion test, were within normal limits. Some patients had weakly positive cephalin
cholesterol flocculation tests after 2 months therapy. It is suggested that this
test be done monthly for 3 months, and then at less frequent intervals, on pa-
tients receiving the drug.
4. The LD50 for adult mice and rats is approximately 400 to 600 mg. per kg.
5. The molecular extinction coefficient for 8-methoxypsoralen and 8-isoamyl-
enepsoralen is given.
6. Solutions of 8-methoxypsoralen before and after exposure to ultraviolet
light have no effect on the tyrosine-, dopa-, or glutathione inhibited- tyrosinase
systems, or on the histochemical skin tests for tyrosinase activity. The solutions
also did not affect the melanocytes of isolated frog skin.
7. The effect of ultraviolet light on the optical density of solutions of 8-meth-
oxypsoralen is shown.
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